Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences reported positive interim Phase 1 results for JADE101, showing approximately 70% IgA reductions sustained at 12 weeks after a single dose in healthy volunteers. The data suggests JADE101 is faster, deeper, and more durable than first-generation anti-APRIL agents, with a potential dosing regimen of one injection every 12 weeks.
Key figures
- Drug Name
- JADE101
- Phase Of Trial
- Phase 1
- Max dose mg
- 1400
- Iga reduction pct
- ~70%
- Phase 3 start window
- H1 2027
- Dosing interval weeks
- 12
- Potency vs povetacicept
- 26-fold
- Potency vs sibeprenlimab
- 379-fold
- Half life vs povetacicept
- 8.7-fold
- Phase 2 enrollment target
- 30
- Half life vs sibeprenlimab
- 2.6-fold
- Iga reduction sustained weeks
- 12
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.